Is UBT251 an approved medicine?
No. It is a research candidate, not an FDA-approved medicine. The authors frame the obesity findings as supporting phase 3 evaluation.
Was retatrutide a comparator?
No. The obesity trial compared UBT251 regimens with placebo. Retatrutide was studied in a separate trial. See cross-trial context.
Why do the headlines use different percentages?
The −19.7% figure is an arm-level week-24 LS mean; −17.7% is a reported placebo-adjusted difference. See endpoint literacy.
Does a larger regimen mean a larger effect?
The observed means do not show a simple monotonic pattern. Numerical ordering is not proof of an optimal regimen, especially with small groups.
Can the figures guide personal dosing?
No. All regimen labels describe trial protocol groups only. This website offers no personal dosing or treatment instructions.
Where can I check the claims?
Start with the source ledger, then examine the original paper and registry. The methods guide explains common interpretation issues.